Search
Major Depressive Disorder Clinical Trials
A listing of 127 Major Depressive Disorder clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 127
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Major Depressive Disorder
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
There are currently 127 active clinical trials seeking participants for Major Depressive Disorder research studies. The states with the highest number of trials for Major Depressive Disorder participants are California, Florida, Texas and New York.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Depression Clinical Trial
Recruiting
Join us in researching a potential investigational treatment for Depression. Reimbursement for study-related expenses may be available to you.
Qualifying participants:
•Are between 18-65
•Have been experiencing a major depressive episode forat least a month
Qualifying participants:
•Are between 18-65
•Have been experiencing a major depressive episode forat least a month
Conditions:
Depression
Major Depressive Disorder
Depressive Disorder
Depressive Symptoms
Depressive Disorder
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression
Recruiting
This study looks at the role of the Nociceptin/Orphanin FQ receptor system in the brain of individuals with current or past major depressive disorder (MDD). It also examines how individuals with a history of depression make certain decisions and which brain regions are involved in such decisions. Information collected through MRI, PET, biospecimens (i.e., blood, saliva) and behavioral tasks will be used to predict depressive symptoms in the future.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
05/06/2025
Locations: McLean Hospital, Belmont, Massachusetts
Conditions: Major Depressive Disorder
Neural Correlates of Stress and Perceived Control in Adolescent Depression
Recruiting
Lack of perceived control, particularly during stress, has been critically implicated in major depressive disorder (MDD) and anhedonic symptoms, especially among female adolescents; yet the neural underpinnings of perceived control disruptions in MDD remain poorly understood. Using functional magnetic resonance imaging with a novel "value of control task" in conjunction with a prospective design, this study will provide a comprehensive understanding of stress and perceived control related mechan... Read More
Gender:
FEMALE
Ages:
Between 14 years and 18 years
Trial Updated:
05/05/2025
Locations: McLean Hospital, Belmont, Massachusetts
Conditions: Major Depressive Disorder
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
Recruiting
This open-label functional Magnetic Resonance Imaging (fMRI) study will assess the effects of a single dose of psilocybin on rumination and the neural correlates of rumination in individuals with major depressive disorder.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
05/05/2025
Locations: Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts
Conditions: Major Depressive Disorder
Testing a Transdiagnostic TMS Treatment Target
Recruiting
The goal of this clinical trial is to test a new brain stimulation treatment target for individuals with depression plus at least one additional psychiatric disorder. The main question is to understand the safety profile of a non-invasive form of brain stimulation called accelerated intermittent theta burst stimulation when it is targeting the posterior parietal cortex. Additional questions focus on whether this stimulation improves symptoms of depression and other psychiatric disorders as well... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/02/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Major Depressive Disorder, Depression, Psychiatric Disorder, Mood Disorders, Mental Disorder, Anxiety Disorders, OCD, PTSD
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
Recruiting
Background:
Most medications that treat depression take weeks or months to work. Researchers want to develop fast-acting treatments. One dose of ketamine has a rapid antidepressant effect. For most people, this lasts a week or less. Repeated doses of ketamine may help maintain this effect.
Objective:
Main Study: To study the effects of ketamine in treating depression.
Ketamine Metabolites Substudy: To study how ketamine effects brain chemistry.
To study how ketamine effects the brain. This... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/02/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression
Recruiting
The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD)
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/01/2025
Locations: Reverie Mind, LLC, Chandler, Arizona +67 locations
Conditions: Major Depressive Disorder
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Recruiting
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Neurocrine Clinical Site, Saint Charles, Missouri
Conditions: Major Depressive Disorder
Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
Recruiting
Study Description:
This study examines relations between neurocognitive and clinical features of pediatric anxiety disorders. The study uses neuro-cognitive tasks, functional magnetic resonance imaging (fMRI), as well as magneto- and electro-encephalography (M/EEG). Patients will be studied over one year, before and after receiving either one of two standard-of-care treatments: cognitive behavioral therapy (CBT) or fluoxetine, a serotonin reuptake inhibitor (SSRI). Healthy comparisons will be s... Read More
Gender:
ALL
Ages:
Between 8 years and 65 years
Trial Updated:
04/30/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Major Depressive Disorder, Anxiety Disorders
Natural History of Depression, Bipolar Disorder and Suicide Risk
Recruiting
Mood disorders, such as depression and bipolar disorder, are difficult to treat. One reason is that there are no objective ways to measure how these disorders affect the body and respond to different treatments. In this study, researchers want to perform tests on people undergoing clinical care for mood disorders. The purpose is to understand the experience of receiving treatment for depression, bipolar disorder, and suicide risk. We also hope that this study will help us to predict which medica... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
04/30/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Behavioral Symptoms, Suicide, Self-Injurious Behavior, Sensory System Agents, Analgesics, Peripheral Nervous System Agents, Physiological Effects of Drugs, Anesthetics, Dissociative, Anesthetics, General, Anesthetics, Central Nervous System Depressants, Excitatory Amino Acid Antagonists, Excitatory Amino Acid Agents, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action, Ketamine, Depression, Unipolar, Depressive Symptoms, Treatment Resistant Depression, Major Depressive Disorder, Depression, Bipolar
Study to Assess the Safety and Effectiveness of NMRA-335140-501
Recruiting
This is a 52-week open-label extension (OLE) study that will evaluate the safety, tolerability, and effectiveness of NMRA-335140 in participants with major depressive disorder (MDD). Participants who completed a parent study investigating the efficacy and safety of NMRA-335140 as a treatment for MDD (ie, NMRA-335140-301, NMRA-335140-302, or NMRA-335140-303), and complete the 6 weeks double-blind treatment, provide informed consent, and meet eligibility criteria, may enter this extension study.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/29/2025
Locations: Neumora Investigator site, Huntsville, Alabama +147 locations
Conditions: Major Depressive Disorder
Clinical Validation of Samsung Smartwatch
Recruiting
Objective:
Wearable technology holds promising potential for mental health monitoring and detection. Samsung has developed an algorithm that they believe can detect signs of depression and anxiety in smartwatch users. They have used this algorithm to create a "Mindfulness Index," which is an easily understood visual index of mental health. The primary aim of the study is to evaluate the performance of Samsung's Mindfulness Index in identifying those who have received a diagnosis of Major Depres... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/28/2025
Locations: Center for Anxiety and Traumatic Stress Disorders, Massachusetts General Hospital, Boston, Massachusetts
Conditions: Major Depressive Disorder, Mood Disorders, Mental Health Issue
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
Recruiting
The purpose of this study is to examine the efficacy, safety, and tolerability of CYB003 compared to matching placebo as adjunctive treatment in participants with MDD.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
04/28/2025
Locations: Noble Clinical Research, Tucson, Arizona +24 locations
Conditions: Major Depressive Disorder
1 - 12 of 127